More recently, the Seattle group reported that 9 patients out of 29 (31%) adult B-ALL patients relapsed, and 3 (33%) of them were CD19-negative (1 myeloid phenotype switch) [17]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.